Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abbott Laboratories (ABT) vs Anheuser-Busch Inbev SA (BUD) Price & Performance

Abbott LaboratoriesTrade
Anheuser-Busch Inbev SATrade

Price performance (Past 24H)

Key statistics

Abbott Laboratories vs Anheuser-Busch Inbev SA — how do they compare? Abbott Laboratories trades at $109.77 (market cap $187.95B), while Anheuser-Busch Inbev SA trades at $79 (market cap $159.01B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.

ABTBUD
Market Cap
$187.95B$159.01B
Sector
HealthConsumer Staples
52-Week High
$136.62$86.48
52-Week Low
$82.57$57.93
Enterprise Value
$214.96B$223.42B
Dividend Yield
2.32%1.67%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abbott Laboratories

Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.

Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.

Anheuser-Busch Inbev SA

BUD trades at $83.09, down 0.8% today, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating in Q1 and Q2 2026 but missing in Q4 2025. The company maintains solid profitability with a 14.9% net income margin and positive cash flow trends. News highlights institutional activity and earnings discussions, with a consensus price target of $90.17 suggesting upside potential.

The outlook for BUD is positive, driven by earnings growth projections and a favorable valuation with a P/E of 17.37. Risks include competitive pressures and macroeconomic volatility, but institutional support and bullish analyst ratings indicate confidence in continued performance. The stock presents a growth opportunity with manageable risks for investors seeking exposure to the consumer staples sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abbott Laboratories

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Read more on ABT

About Anheuser-Busch Inbev SA

Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.

Read more on BUD